Wnt5a, Ryk and Ror2 expression in glioblastoma subgroups
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Yuil | - |
dc.contributor.author | Hong, Mineui | - |
dc.contributor.author | Do, In-Gu | - |
dc.contributor.author | Ha, Sang Yun | - |
dc.contributor.author | Lee, Dakeun | - |
dc.contributor.author | Suh, Yeon-Lim | - |
dc.date.accessioned | 2024-01-09T01:05:24Z | - |
dc.date.available | 2024-01-09T01:05:24Z | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 0344-0338 | - |
dc.identifier.issn | 1618-0631 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/69740 | - |
dc.description.abstract | Background: Wnt5a, a non-canonical Wnt ligand, has been shown to play tumor-promoting or tumor-suppressive roles in different neoplasms. Increased Wnt5a expression and Wnt5a-dependent invasive activity that is mediated by one of its receptors, Ryk, have been reported in glioblastomas. Methods: We investigated the protein expression of Wnt5a, its receptors Ryk and Ror2, and the canonical Wnt pathway marker P-catenin in 186 cases of glioblastoma and its variants. Associations with clinicopathological and molecular variables and prognosis were analyzed. Results: All glioblastoma cases expressed Wnt5a, Ryk and Ror2 with a different grade. The expression of both Ryk and Ror2 correlated with that of Wnt5a in glioblastomas. The expression of p-catenin did not correlate with any of Wnt5a, Ryk or Ror2. Wnt5a expression was significantly different among subgroups of the glioblastoma. However, none of Wnt5a, Ryk or Ror2 had a prognostic impact on glioblastoma. For P-catenin, a shorter progression-free survival was noted in the glioblastoma with oligodendroglioma component (GBMO) subgroup. Conclusions: Our results corroborated previous findings of Rylc-mediated Wnt5a effect, and suggested a role for Ror2 in the Wnt5a machinery in glioblastoma. (C) 2015 Elsevier GmbH. All rights reserved. | - |
dc.format.extent | 10 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | ELSEVIER GMBH | - |
dc.title | Wnt5a, Ryk and Ror2 expression in glioblastoma subgroups | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.prp.2015.10.001 | - |
dc.identifier.bibliographicCitation | PATHOLOGY RESEARCH AND PRACTICE, v.211, no.12, pp 963 - 972 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000367425200011 | - |
dc.identifier.scopusid | 2-s2.0-84954460513 | - |
dc.citation.endPage | 972 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 963 | - |
dc.citation.title | PATHOLOGY RESEARCH AND PRACTICE | - |
dc.citation.volume | 211 | - |
dc.type.docType | Article | - |
dc.publisher.location | 독일 | - |
dc.subject.keywordAuthor | Wnt5a | - |
dc.subject.keywordAuthor | Ryk | - |
dc.subject.keywordAuthor | Ror2 | - |
dc.subject.keywordAuthor | beta-Catenin | - |
dc.subject.keywordAuthor | Glioblastoma | - |
dc.subject.keywordPlus | SIGNALING PATHWAY | - |
dc.subject.keywordPlus | BETA-CATENIN | - |
dc.subject.keywordPlus | PROLIFERATION | - |
dc.subject.keywordPlus | ACTIVATION | - |
dc.subject.keywordPlus | MARKERS | - |
dc.subject.keywordPlus | GLIOMA | - |
dc.subject.keywordPlus | IDH1 | - |
dc.relation.journalResearchArea | Pathology | - |
dc.relation.journalWebOfScienceCategory | Pathology | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.